A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

References

• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–12. doi:10.1038/nrd4591.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153–167. doi:10.1038/nri.2017.108.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034. doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–1086. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309–5337. doi:10.1016/j.cell.2021.09.020.
   PubMed Web of Science ®Google Scholar
• Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov. 2021;20:899–919. doi:10.1038/s41573-021-00155-y.
   PubMed Web of Science ®Google Scholar
• Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. doi:10.1016/j.phrs.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253–275. doi:10.1016/j.semcancer.2022.04.002.
   PubMed Web of Science ®Google Scholar
• Antibody therapeutics approved or in regulatory review in the EU or US [Internet]. The Antibody Society. [accessed 2023 March 1]. https://www.antibodysociety.org/resources/approved-antibodies/
   Google Scholar
• Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010;28:355–362. doi:10.1016/j.tibtech.2010.03.007.
   PubMed Web of Science ®Google Scholar
• Cuesta AM, Sánchez-Martín D, Blanco-Toribio A, Villate M, Enciso-Álvarez K, Álvarez-Cienfuegos A, Sainz-Pastor N, Sanz L, Blanco FJ, Álvarez-Vallina L. Improved stability of multivalent antibodies containing the human collagen XV trimerization domain. MAbs. 2012;4:226–232. doi:10.4161/mabs.4.2.19140.
   PubMed Web of Science ®Google Scholar
• Lazarovici P, Lelkes PI. Pardaxin induces exocytosis in bovine adrenal medullary chromaffin cells independent of calcium. J Pharmacol Exp Ther. 1992;263:1317–1326.
   PubMed Web of Science ®Google Scholar
• Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Cuesta AM, Blanco-Toribio A, Harwood SL, Villate M, Merino N, Bonet J, Navarro R, et al. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Sci Rep. 2016;6:28643. doi:10.1038/srep28643.
   PubMed Web of Science ®Google Scholar
• Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293:1155–1159. doi:10.1126/science.1061692.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–242. doi:10.1093/nar/28.1.235.
   PubMed Web of Science ®Google Scholar
• Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403–410. doi:10.1016/S0022-2836(05)80360-2.
   PubMed Web of Science ®Google Scholar
• Liu S, Miersch S, Li P, Bai B, Liu C, Qin W, Su J, Huang H, Pan J, Sidhu SS, et al. A synthetic human antibody antagonizes IL-18Rβ signaling through an allosteric mechanism. J Mol Biol. 2020;432:1169–1182. doi:10.1016/j.jmb.2020.01.012.
   PubMed Web of Science ®Google Scholar
• Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res. 2003;9:2316–2326.
   PubMed Web of Science ®Google Scholar
• Meira DD, Nóbrega I, de Almeida VH, Mororó JS, Cardoso AM, Silva RLA, Albano RM, Ferreira CG. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway. Eur J Cancer. 2009;45:1265–1273. doi:10.1016/j.ejca.2008.12.012.
   PubMed Web of Science ®Google Scholar
• Schmitz KR, Bagchi A, Roovers RC, van Bergen En Henegouwen PMP, Ferguson KM. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure. 2013;21:1214–1224. doi:10.1016/j.str.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8:593–603. doi:10.1080/19420862.2015.1136043.
   PubMed Web of Science ®Google Scholar
• Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A. Product review on the Anti-PD-L1 antibody atezolizumab. Human Vacc Immunother. 2018;14:269–276. doi:10.1080/21645515.2017.1403694.
   PubMed Web of Science ®Google Scholar
• Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, Van Bergen En Henegouwen PMP, Lykkemark S, et al. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology. 2017;7:e1377874. doi:10.1080/2162402X.2017.1377874.
   PubMed Web of Science ®Google Scholar
• Surowka M, Schaefer W, Klein C. Ten Years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs. 2021;13:1967714. doi:10.1080/19420862.2021.1967714.
   PubMed Web of Science ®Google Scholar
• Blanco B, Domínguez-Alonso C, Alvarez-Vallina L. Bispecific immunomodulatory antibodies for cancer immunotherapy. Clin Cancer Res. 2021;27:5457–5464. doi:10.1158/1078-0432.CCR-20-3770.
   PubMed Web of Science ®Google Scholar
• Esfandiari A, Cassidy S, Webster RM. Bispecific antibodies in oncology. Nat Rev Drug Discov. 2022;21:411–412. doi:10.1038/d41573-022-00040-2.
   PubMed Web of Science ®Google Scholar
• Henricks LM, Schellens JHM, Huitema ADR, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev. 2015;41:859–867. doi:10.1016/j.ctrv.2015.10.008.
   PubMed Web of Science ®Google Scholar
• Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies - PubMed [Internet]. [accessed 2022 December 19]. https://pubmed.ncbi.nlm.nih.gov/22925968/
   Google Scholar
• Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao S-W, Lencer WI, Pierce GF, Blumberg RS. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015;35:235–254. doi:10.3109/07388551.2013.834293.
   PubMed Web of Science ®Google Scholar
• Clarke SC, Ma B, Trinklein ND, Schellenberger U, Osborn MJ, Ouisse L-H, Boudreau A, Davison LM, Harris KE, Ugamraj HS, et al. Multispecific antibody development platform based on human heavy chain antibodies. Front Immunol. 2019;9:3037. doi:10.3389/fimmu.2018.03037.
   PubMedGoogle Scholar
• Labrijn AF, Meesters JI, de Goeij BECG, van den Bremer ETJ, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. 2013;110:5145–5150. doi:10.1073/pnas.1220145110.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol. 2021;10:56. doi:10.1186/s40164-021-00250-1.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Marvin JS, Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin. 2005;26:649–658. doi:10.1111/j.1745-7254.2005.00119.x.
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677–681. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–106. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• J-H H, Kim J-E, Kim Y-S. Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol. 2016;7:394. doi:10.3389/fimmu.2016.00394.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617–621. doi:10.1093/protein/9.7.617.
   PubMedGoogle Scholar
• Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, Álvarez-Vallina L. The coming of age of engineered multivalent antibodies. Drug Discov Today. 2015;20:588–594. doi:10.1016/j.drudis.2015.02.013.
   PubMed Web of Science ®Google Scholar
• Thomas R, Weihua Z. Rethink of EGFR in cancer with its kinase independent function on board. Front Oncol. 2019;9:800. doi:10.3389/fonc.2019.00800.
   PubMed Web of Science ®Google Scholar
• Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–1363. doi:10.1158/2159-8290.CD-13-0310.
   PubMed Web of Science ®Google Scholar
• Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-Driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10:910–923. doi:10.1097/JTO.0000000000000500.
   PubMed Web of Science ®Google Scholar
• Koopmans I, Hendriks D, Samplonius DF, Ginkel RJ, Heskamp S, Wierstra PJ, Bremer E, Helfrich W. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology. 2018;7:e1466016. doi:10.1080/2162402X.2018.1466016.
   PubMed Web of Science ®Google Scholar
• Li L, Deng L, Meng X, Gu C, Meng L, Li K, Zhang X, Meng Y, Xu W, Zhao L, et al. Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing. Transl Oncol. 2021;14:100916. doi:10.1016/j.tranon.2020.100916.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Lenz H-J, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M, Milano G. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018;63:48–60. doi:10.1016/j.ctrv.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie H-B, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen–specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858–1872. doi:10.1158/1078-0432.CCR-12-2426.
   PubMed Web of Science ®Google Scholar